Option chain shows key data for Clearmind Medicine's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Clearmind Medicine.

Clearmind Medicine (NASDAQ:CMND) Stock, Option Chain

Clearmind Medicine

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

benzingaai2023_stock_market_charts_on_multiple_computer_scree_03ada781-be05-460b-a6af-38988bc7658b_1

News

Movers

CMND

SPRC

SciSparc Ltd (NASDAQ:SPRC) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc (NASDAQ:CMND) led to a patent application for psychedelic therapy targeting cocaine addiction.

SciSparc Shares Are Soaring Monday: What&#39;s Going On?

Cannabis

Health Care

Trading Ideas

General

SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial.

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

Markets

PSIL

Clearmind Medicine&#39;s stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder.

Why Is Penny Stock Clearmind Gaining Today?

Clearmind Medicine Inc

Legal

Press Releases

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Clearmind Medicine Announces Shareholders Meeting Results

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

Comments

Clearmind Medicine

Clearmind Medicine (CMND) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga